Creative Medical Technology (NASDAQ:CELZ) Stock Rating Upgraded by Wall Street Zen

Creative Medical Technology (NASDAQ:CELZ) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings cut Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Creative Medical Technology has a consensus rating of “Hold”.

Creative Medical Technology Stock Performance

NASDAQ:CELZ opened at $0.96 on Friday. The firm has a market capitalization of $6.33 million, a PE ratio of -0.46 and a beta of 2.04. The stock has a 50 day moving average of $1.01 and a 200-day moving average of $1.68. Creative Medical Technology has a 52 week low of $0.62 and a 52 week high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, analysts predict that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC bought a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.